Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP

Voyager Therapeutics, Inc. VYGR

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$40.4M
▼ 49.5% YoY
$-119.7M
$-135.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Many of the company's programs are derived from its TRACER adeno-associated virus (AAV) capsid discovery platform, which it has used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of the company's programs are wholly-owned, and some are advancing with licensees and collaborators, including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Transition Bio, Inc. The company leases its office and laboratory space, consisting of approximately 26,148 square feet located in Cambridge, Massachusetts and 93,449 square feet located in Lexington, Massachusetts. As of December 31, 2025, the company employed 141 full-time employees in the United States, including 112 in research and development positions and 29 in general and administrative positions.

Written from the business description in Voyager Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 9 March 2026. Every sentence was checked against that document before publication.

Growth

USD 40.4M
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 40.4 · Net income -119.7
100M200M-50M-100M
20142017202020232025
Compound annual growth
−0.4%
−25.1%
+8.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −25.1% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−297 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -326.6% · Net -296.5%
-500%-1000%
201420192025
ROE
FY2025 · ROE -48.3%
50%-50%
201420192025
Three returns, three denominators.

Each USD of equity lost 48 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -135.1
30M60M-50M-100M
201420192025

Total assetsUSD 252.3M
EquityUSD 196.1M
CashUSD 65.3M
Current ratio7.64×

Equity funds 78% of total assets.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
VYGR, 12-year financial record
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.00.10.30.00.00.20.10.00.00.00.0◌
Operating income $B−0.1−0.10.1−0.1−0.10.0−0.1−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.1−0.10.1−0.0−0.10.0−0.0−0.1−0.1−0.0−0.0−0.0
Income tax $B0.00.00.00.0◌◌◌−0.0◌0.00.0◌
Net income $B−0.1−0.10.1−0.0−0.10.0−0.0−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.1−0.00.1−0.0−0.1−0.10.0−0.0−0.1−0.00.0−0.0
EPS, diluted $−2.04−1.132.97−1.21−1.890.98−1.21−2.75−2.64−1.599.1427.83
Dividend / sh $◌◌◌◌0.000.000.000.00◌◌0.00◌
Payout % — not applicable: no dividend————————————
ROE %−48.3−24.389.6−60.2−57.128.9−59.7−97.8−52.4−26.4——
Shares out B0.060.050.040.040.040.040.040.030.030.030.020.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 2 failures in 49 reconciliationsAUDITED

Reconciled in 10 of the 12 fiscal years we could check. 14 checks were skipped: the balance sheet is not tagged before 2014. Seven checks were skipped: EPS is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency2 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image